Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials-Reference-Cited by-同舟云学术

Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials

Published:2017-04-04 Issue:2 Volume:106 Page:229-239
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Suh Koung Jin,Lee Ji Yun,Shin Dong-Yeop,Koh Youngil,Bang Soo-Mee,Yoon Sung-Soo,Park Seonyang,Kim Inho,Lee Jeong-Ok^ORCID

Funder

Seoul National University Bundang Hospital Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-017-2225-1/fulltext.html

Reference32 articles.

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

2. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–40.

3. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54.

4. Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317–24.

5. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107–12.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management;Signal Transduction and Targeted Therapy;2023-07-07

2. The Potential Protective Role of Naringenin against Dasatinib-Induced Hepatotoxicity;Pharmaceuticals;2023-06-23

3. Safety and Tolerability of Nilotinib in Patients with Chronic Myeloid Leukemia during Routine Clinical Practice: Results from the ERASER Study from Greece;Journal of Clinical Haematology;2022-12-13

4. The Role of Bosutinib in Chronic Myeloid Leukemia: An Indian Perspective;Indian Journal of Medical and Paediatric Oncology;2022-11-28

5. Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event;Frontiers in Oncology;2022-09-13